Hi everyone, In this edition of the LC Weekly, we look into the pivotal role of patient-led research and the evolving landscape of treatment trials. The seminal paper in 2021 by the Patient-Led Research Collaborative has not only advanced our understanding of Long COVID but also underscored the necessity of patient contributions to high-quality research. Meanwhile, recent studies reveal the limitations of antiviral drugs like Paxlovid in shortening COVID-19 symptoms in fully vaccinated individuals, alongside the heightened risks for patients with unmet social needs developing severe Long COVID symptoms and neuropsychiatric sequelae. Moreover, we explore research into the immune responses of discharged COVID-19 patients, the incidence of allergic diseases post-COVID, and the impact of post-COVID pain on quality of life.
I especially liked two articles on the possible neurocognitive effects of the virus. I had a CT/PET scan done two days ago and will keep you posted of anything relevant they discover!
So many interesting studies here - thank you! Was there any mention of activated mast cells in the study about allergies?
Thanks for the Webby award link too. Her graphic depiction of love with LC was truly a work of art (and so accurate). I will link in my newsletter too.
I especially liked two articles on the possible neurocognitive effects of the virus. I had a CT/PET scan done two days ago and will keep you posted of anything relevant they discover!
Michael (class of 2020)
So many interesting studies here - thank you! Was there any mention of activated mast cells in the study about allergies?
Thanks for the Webby award link too. Her graphic depiction of love with LC was truly a work of art (and so accurate). I will link in my newsletter too.